microbiology-fungal-infections-2019-scientifictracks

2 / 8

Page 14
Volume 3 Microbiology 2019 & Fungal infections 2019
October 07-08, 2019
Journal of Clinical Microbiology and Infectious diseases
October 07-08, 2019 | Madrid, Spain
MICROBIOLOGY AND MICROBIOLOGISTS
MYCOLOGY AND FUNGAL INFECTIONS
2 nd Annual Congress on
6th International Conference on
&
J Clin Microbiol Infect Dis, Volume 3
Molecular fingerprints of anti- Candida antibodies in serum: A mine for clinical
biomarker development invasive candidiasis
Aida Pitarch Velasco
Complutense University of Madrid, Spain
Statement of the Problem: Despite great advances in antifungal therapy, invasive candidiasis (IC) remains a significant public
health problem worldwide. This opportunistic fungal infection caused by Candida spp. (commonly Candida albicans) often
results in delayed initiation of appropriate antifungal therapy and poor clinical outcomes. We investigated whether molecular
profiling of the serum IgG- antibody responses to the C. albicans immunome could reveal diagnostic and prognostic signatures
that may serve to devise diagnostic and clinical-outcome prediction models for IC and contribute to known clinical factors.
Methodology & Theoretical Orientation: We combined serological proteome analyses (two-dimensional gel electrophoresis
followed by Western blot analysis and mass spectrometry) with data mining procedures to explore the serum IgG- antibody
responses to C. albicans protein species in IC and non-IC patients.
Findings: Unsupervised two-way hierarchical clustering and principal-component analyses of these IgG antibody-reactivity
patterns accurately discriminated IC patients from non-IC patients as well
as IC survivors from IC non-survivors. Supervised discriminant analyses
identified two-IgG and five-IgG antibody-reactivity signatures as the most
simplified and accurate IC diagnostic and prognostic predictors, respectively.
Multivariate logistic-regression analyses revealed a positive association
between these predictors and IC risk or two-month death risk. Receiver-
operating characteristic curve analyses indicated that these diagnostic and
clinical-outcome predictors for IC outperformed known clinical factors.
Further validation of molecular fingerprints of these anti-Candida IgG
antibodies in serum on multiplexed immunoassays substantiated the
serological proteome analysis results (Figure 1).
Conclusion & Significance: We conclude that these prediction models may
be useful to reliably diagnose IC and predict patient clinical-outcome for individualized therapy of IC. Our study shed new light
on the anti- Candida IgG antibody response development in IC, and further highlights the importance of defining pathogen-
specific antigens at the chemical and molecular level for their potential use as diagnostic or prognostic reagents or vaccine
candidates for infectious diseases.
Biography
Aida Pitarch Velasco has her expertise in the clinical biomarker development for infectious diseases and in translational research. She
has identified a large panel of novel clinical biomarkers and therapeutic candidates for invasive candidiasis. She has built diagnostic
and clinical-outcome prediction models for these life-threatening fungal infections based on molecular fingerprints of the serologic
responses to the Candida immunome. She has also developed new prototype immunological assays for the diagnosis and prognosis
of invasive candidiasis. Her studies have further contributed to unraveling the great diversity and complexity associated with the
pathogen-encoded immunome.
Figure 1. Diagnostic and prognostic biomarkers for IC
discovered and validated in this study by serological proteome
analysis and multiplexed protoype immunoassays, respectively